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Umbilical cord blood is a source of haematopoietic progenitor cells, which are
used to treat a range of malignant, genetic, metabolic and immune disorders.
Until recently, cord blood was either collected through donations to publicly
funded cord blood banks for use in allogeneic transplantation, or stored in
commercial cord blood banks for use in autologous transplantation. The line
between public and private cord blood banking is being blurred by the
emergence of “hybrid” models that combine aspects of both the public and
private systems. The authors describe these hybrid models and argue that
their emergence is explained by both market forces and public sector policy.
They propose that the future of the sector will depend heavily on several key
developments that will differentially affect public, private and hybrid banking
models.
INTRODUCTION
Umbilical cord blood is a rich source of haematopoietic progenitor cells which can be used to treat a
range of malignant, genetic, metabolic and immune disorders. For the purpose of transplantation,
haematopoietic progenitor cells sourced from cord blood have several advantages over those sourced
from bone marrow or peripheral blood. Cord blood is widely available and easily accessible;
collection is relatively non-invasive, safe and painless; and because haematopoietic progenitor cells
derived from cord blood are immunologically naïve, they can be safely infused even when they are an
incomplete match for the recipient.1 Furthermore, in recent years the high rates of infection and graft
failure evident in early studies of cord blood transplantation, which related to the low numbers of
haematopoietic progenitors in single cord blood units, have been largely overcome by the practice of
“double cord” transplantation, where two cord blood units are transplanted into the recipient.2
Cord blood was first used successfully for allogeneic transplantation in 19883 and the first
publicly funded cord blood bank was established in New York in 1993. Worldwide to date, over
15,000 allogeneic cord blood transplants have been performed and there are more than 53 public cord
blood banks which store donated cord blood for public access. These banks are listed on national and
international registries and networks that can be searched by clinicians who are looking for a donor for
a child or adult requiring a transplant. For example, Bone Marrow Donors Worldwide (BMDW)
currently lists 44 cord blood banks from 26 different countries and contains 446,817 units of cord
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blood.4 Currently in the United States, more than 50% of haematopoietic progenitor cell transplants
from unrelated donors to children are sourced from cord blood.5
Donation of cord blood is based on communitarian values such as altruism and social solidarity.6
The act of donation, the public banks that enable it and the international networks and registries that
connect them are thus widely regarded as social goods, along with other systems of tissue and organ
donation and volunteering. In most developed countries, therefore, donors are protected by ethical
guidelines and there is a high level of cooperation between government agencies and scientific and
medical bodies to protect the supply of cord blood for allogeneic transplantation, and to develop and
promote the public system of donation.
Soon after public cord blood banks were established, a parallel commercial industry emerged as
private banks began offering to store a child’s cord blood on a fee-for-service basis for personal
(autologous) or family use. There are currently approximately 225 private cord blood banks
worldwide.7 Approximately 800,000 cord blood units are stored in private banks, which far exceeds
the number stored by international stem cell registries for public use.8
Private cord blood banks differ from public banks in terms of both their medical rationale and the
values on which they are based. Currently, there are few clinical indications for autologous transplants
using stored cords.9 Cord blood is stored privately largely on the assumption that it will eventually
prove to be an important source of haematopoietic progenitor cells for regenerative medicine.
Regenerative medicine remains little more than a promising possibility, however, and although some
clinical trials are currently underway, the value of cord blood in this wider enterprise also remains
uncertain. The medical utility of private cord blood banks is thus more potential than actual, and as a
consequence, their emergence has been attended by controversy on the grounds, eg, that they threaten
the supply of cords to the public system; that they displace proven therapeutic uses of cord blood with
uses whose benefits are largely speculative; that misleading claims are made about the magnitude of
those benefits; and that commercialisation displaces relationships of solidarity in a global community
with contractual relationships in a commercial market.10 Notwithstanding this, private banks have
evidently enjoyed a measure of commercial success. They market their services by tapping into
parents’ sense of obligation towards their own children, and parents’ anxiety that they may in future
regret having missed the opportunity to protect their children and feel guilty for doing so.11 Private
storage of cord blood is thus marketed and consumed as a form of “biological insurance” taken out by
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“good parents” to safeguard their children’s future, and is therefore based on the neo-liberal principles
of private insurance, which offers personalised risk-management services as a hedge against future
uncertainties.12
Until recently, only one alternative has stood intermediate between public donation and private
storage, that being the option of “directed donation” of cord blood donated to public banks to siblings
who have an existing condition that may in future require an allogeneic transplant. The line between
public and private cord blood banking is being increasingly blurred by the emergence of “hybrid
models” that combine aspects of both the public and private systems. The remainder of this article
describes these hybrid models, offers an explanation for their emergence, and describes three factors
that are likely to play a major role in determining how they are likely to evolve.
HYBRID MODELS OF CORD BLOOD BANKING
Hybrid models of cord blood banking fall into two broad categories (Table 1). First, instead of offering
parents either public donation or private storage, some banks are now offering both options. Many
private cord blood banks have adopted this strategy, including Lifeforce Cryobanks in the United
States and Cryosave in Belgium. To date, the only public bank in the world to offer both options is the
Alberta Cord Blood Bank in Canada.
TABLE 1 Hybrid models of umbilical cord blood banking
Type of hybrid Model Description
Cord blood banks that offer both
public donation and private
storage options
Private banks that offer
a public donation
option
Several private banks now offer to store donated cord
blood for use in allogeneic transplants, eg Lifeforce
Cryobanks in the United States, Eticur in Germany,
Eurocord in Slovakia and Cryosave in Belgium (which
provides the not-for-profit health foundation Osidea with
storage facilities for donated cord blood).
Public banks that offer
a private storage
option
Since 2005 the Alberta Cord Blood Bank in Canada has
offered a private storage option to generate funding.
Innovations that make privately
stored blood available to the
public system
Turkish model According to government legislation, 25% of all privately
stored cord blood is donated to the public system.
Spanish model Cord blood stored in a private bank is recorded on the
Official Spanish Register of Bone Marrow Donors.
Should a patient in need of a transplant find a correct
human leukocyte antigen match, parents are obliged to
donate the cord blood and the storage fee is reimbursed.
Virgin model 80%of the cord blood is donated to the public sector and
20% is stored for private use. Profits are used to fund
stem cell research.
Private banks that
provide an option to
release stored cord
blood for public use
Several German banks offer parents the option of
privately storing cord blood which can be released for
use if it is matched to a patient who needs an allogeneic
transplant. Parents are under no obligation to release the
blood if a match is found. VITA34 bank offers this as an
option called VitaplusSpende and Eticur offer this as an
option called Eticur:Kombi. Both banks also offer parents
the option of storing cord blood privately for autologous
use only.
Secondly, other banks make privately stored cord blood available to the public system of
donation. This is has been achieved in Turkey and Spain by legislative means. The Virgin model in the
United Kingdom achieves the same outcome by splitting each individual unit of cord blood so that
80% is donated to the public system for allogeneic transplantation and 20% is stored privately for
12 Manegold et al, n 8 at 99-104.
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future autologous use, with the profits used to fund stem cell research. Other private banks such as
VITA34 and Eticur in Germany offer parents the option of releasing privately stored cord blood if it is
matched to a patient who needs it for an allogeneic transplant.
INFLUENCES DRIVING THE EMERGENCE OF HYBRID MODELS
The emergence of hybrid models of cord blood banking reflects the influence of both market forces
and public sector policy. It also reflects public support for organ and tissue donation and
transplantation programs, and private storage.13 Hybrid models such as those developed by Virgin,
VITA34 and Eticur are, therefore, likely to appeal to a wider market because they cater to both
communitarian and neo-liberal values rather than forcing parents to choose between them.
Hybrid models of cord blood banking can also be understood as a response to the threat of state
intervention. Some governments, including those of Italy, France, Belgium and Luxembourg, have
sought to protect the public system and the communitarian values underpinning it by prohibiting
private cord blood banks altogether. Measures introduced by the governments of Turkey and Spain are
clearly designed to achieve the same ends by less restrictive means. In Turkey, cord blood can be
privately stored but the government has legislated that 25% of the banks’ cord blood units must be
offered to the public system14 to ensure a sufficient supply of haematopoietic progenitor cells for
allogeneic transplantation. Spain also allows private storage of cord blood, but stored cords must be
recorded on the official Spanish Registry of Bone Marrow Donors and made available to any patient
who requires them for an allogeneic transplant.
The hybrid models introduced by private banks can therefore be explained as both prudential
measures as well as marketing strategies. By making privately stored blood available to the public
system on their own accord, private banks weaken the warrant for legislation or regulatory controls
that would force this to happen on terms that are not of their own choosing, or that would curtail their
business entirely.
The hybrid model introduced by the public cord blood bank in Alberta, Canada, is also a response
to public policy in the sense that it is an attempt to compensate for lack of public funding. Other
public banks with the same problem might be expected to follow suit.
FACTORS THAT WILL SHAPE THE FUTURE OF HYBRID MODELS
Future directions in cord blood banking will depend heavily on several factors that will impact
differentially on public and private banks and their hybrid offspring. One factor is the degree to which
the promises of regenerative medicine are realised. A related factor is the importance that
haematopoietic progenitor cells derived from cord blood turn out to have in this emerging field. If the
promises of regenerative medicine are realised, and if cord blood proves to be a useful resource for
regenerative therapies, then the demand for private storage of cord blood is likely to increase. This
may reduce the supply of cords to the public system and increase the profitability of banks that offer
a private storage option. Clinical trials of autologous cord blood transplants for cerebral palsy and
juvenile diabetes are already underway,15 but ongoing uncertainty about the promise of regenerative
medicine and the place that cord blood has in it has led to private storage being characterised as a
practice grounded more in hope than in evidence.16
Another factor that will impact on the future of cord blood banking is the emergent possibility of
in vitro expansion of haematopoietic progenitor cells derived from cord blood – recently reported by a
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team led by John Rasko in Australia.17 This development may have considerable implications for
hybrid models that divide cord blood units. While dividing single cords between public donation and
private storage may currently decrease their clinical utility, making them unsuitable for either
allogeneic or autologous transplantation, should in vitro expansion of haematopoietic progenitor cells
derived from cord blood becomes widely available, it will be possible, at least in principle, for parents
to both donate to public banks and store cord blood privately without compromising its clinical utility.
This would clearly favour hybrid models of cord blood banking such as the Virgin model.
Yet another factor that will impact on cord blood banking is the emergence of clinical alternatives
to cord blood transplantation – most notably the use of bone marrow or peripheral blood
haematopoietic progenitor cells from haploidentical donors. Haploidentical donors are already being
used more frequently for the purpose of allogeneic transplantation, and indications are that they may
increasingly be used in preference to cord blood.18 Currently, the main disadvantages with this type of
transplant are high rates of graft-versus-host disease, graft failure, disease relapse and infection due to
delayed immune reconstitution.19 If the outcomes of haploidentical transplants continue to improve,
however, this form of transplantation may make public cord blood donation relatively less important,
and the costs associated with maintaining public cord blood banks less easy to justify. Such a
development would, in turn, favour banks that offer a private storage option by removing competition
from public banks altogether.
CONCLUDING COMMENTS
The public-private divide that has, until recently, characterised umbilical cord blood banking reflects
the more fundamental division of many modern societies into public and private sectors that are each
underpinned by different values. The emergence of public banks is an expression of social values such
as cooperation, altruism, social solidarity, collective social responsibility and ethical citizenship. The
emergence of private banks is an expression of commercial values such as competition, speculation,
innovation and profit. Hybrid models of cord blood banking have recently emerged which combine
aspects of both public donation and private banking. These can be understood as the outcome of both
market forces and measures undertaken to defend public banking against competition from
commercial markets. The future of these hybrid models depends heavily on a number of recent
developments in biomedical research and clinical medicine, including regenerative medicine, in vitro
expansion of haematopoietic progenitor cells and the use of bone marrow from haploidentical donors.
Each of these developments will favour or disfavour commercial storage of cord blood, the public
system of donation, and emerging hybrid models in the different ways outlined above.
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